Since August, we’ve treated almost 600 patients with Regen-COV, a monoclonal antibody therapy for treatment and prophylaxis of COVID-19 (and updated since last summer to fight resistant strains.) We recently surveyed those who received Regen-COV during the month of August. 274 people responded and of those, 264 people were treated at BreatheMD. Because approximately half of the people treated at BreatheMD did not respond to the survey, caution should be taken when interpreting the results. We have had no reported incidents of serious, permanent side effects or death.
* No serious, permanent side effects have been found.
